# Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)

> **NCT04567329** · PHASE3 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 620 (actual)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** NOV03
- **DRUG:** Saline Solution

## Key facts

- **NCT ID:** NCT04567329
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-18
- **Primary completion:** 2021-08-30
- **Final completion:** 2021-08-30
- **Target enrollment:** 620 (ACTUAL)
- **Last updated:** 2024-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04567329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04567329, "Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04567329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*